Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
NCT07291063
·
clinicaltrials.gov ↗
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Cholangiocarcinoma
Interventions
DRUG:
Anti-PD-1/PD-L1 antibody
DRUG:
Gemcitabine and Cisplatin Chemotherapy
Sponsor
Shanghai Zhongshan Hospital